A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period
Sponsor: Eli Lilly and Company
This PHASE3 trial investigates Plaque Psoriasis and is currently completed. Eli Lilly and Company leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — Nov 2019 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Aug 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augsburg, Germany , Berlin, Germany , Bochum, Germany , Bonn, Germany , Buxtehude, Germany , Dresden, Germany , Erlangen, Germany , Essen, Germany , Frankfurt, Germany , Friedrichshafen, Germany and 11 more locations